Moreover, several resectable NSCLC patients harbouring a ROS1 fusion or RET fusion have achieved satisfactory pathological outcomes after neoadjuvant therapy with corresponding TKIs [34–37], while whether neoadjuvant immunotherapy could benefit these patients should still be further verified. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.